{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:01:22Z","timestamp":1782255682247,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":615,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>Autologous hematopoietic stem cell (HSC) transplantation is a treatment strategy for restoring normal hematopoietic function in patients with select hematologic malignancies. The number of CD34<jats:sup>+<\/jats:sup> cells available for transplantation has been reported to be the strongest predictor of transplantation success, as measured by rapid and durable hematopoietic recovery. Currently granulocyte colony\u2010stimulating factor (G\u2010CSF) alone or G\u2010CSF plus chemotherapy are the most commonly used methods for stem cell mobilization. Unfortunately 5\u201330% of patients do not respond to these agents. Plerixafor is a new HSC mobilizing drug that antagonizes the binding of chemokine stromal\u2010cell\u2010derived factor\u20101a (SDF\u20101\u03b1) to CXC chemokine receptor 4 (CXCR4). It is indicated in combination with G\u2010CSF to mobilize HSC to the peripheral blood for collection and subsequent autologous transplantation in patients with non\u2010Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Results of clinical trials have shown that plerixafor plus G\u2010CSF allow for the collection of a high yield of HSC with fewer apheresis sessions in patients with NHL and MM. Plerixafor has also shown promising results in small studies enrolling patients with Hodgkin's lymphoma. Moreover, for patients who fail G\u2010CSF mobilization alone, plerixafor with G\u2010CSF may be useful as a salvage mobilization strategy. Overall, plerixafor has been generally well tolerated with adverse effects classified as mild to moderate. The most common adverse effects reported in randomized clinical trials were injection site reactions and diarrhea, with approximately 33% of patients experiencing these effects. To our knowledge, clinical trials comparing G\u2010CSF plus plerixafor with G\u2010CSF plus chemotherapy and cost\u2010effectiveness analyses have not been published; therefore, questions remain regarding the optimal role of plerixafor in the clinical practice setting.<\/jats:p>","DOI":"10.1592\/phco.30.5.485","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T07:22:41Z","timestamp":1272007361000},"page":"485-492","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Plerixafor: A Peripheral Blood Stem Cell Mobilizer"],"prefix":"10.1002","volume":"30","author":[{"given":"Mika R.","family":"Kessans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy L.","family":"Gatesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise R.","family":"Kockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_1_4_2","first-page":"521","article-title":"The role of hematopoietic stem cell transplantation in non\u2010Hodgkin lymphoma","volume":"4","author":"Villanueva ML","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_1_5_2","unstructured":"Center for International Blood and Marrow Transplant Research.Current use and outcomes of hematopoietic stem cell transplantation 2007. Available fromwww.cibmtr.orgABOUTAnnual_ReportArchiveDOCS2007_annual_report.pdf. Accessed July 1 2009."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0805626"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.1999.11746443"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2004.13.598"},{"key":"e_1_2_1_9_2","first-page":"2424","volume-title":"Cancer principles and practice of oncology","author":"Cooper DL","year":"2005"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.07.004"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208785061427"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1360"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:HIJO.0000032355.66152.b8"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.410"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.131"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni813"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2547"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1824"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04107.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2007.08.002"},{"key":"e_1_2_1_21_2","unstructured":"Genzyme Corporation.Mozobil (plerixafor) package insert. Cambridge MA;2008."},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"DeClercqE.The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).Biochem Pharmacol2009;1655\u201364.","DOI":"10.1016\/j.bcp.2008.12.014"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1667-1673.2000"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0663"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.011"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.10.018"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04222.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0663"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0468"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G\u2010CSF versus placebo and G\u2010CSF to mobilize hemato\u2010poietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio JF","year":"2009","journal-title":"Blood"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.V112.11.1136.1136","article-title":"12\u2013months report from the phase 3 study of plerixafor + G\u2010CSF vs. placebo + G\u2010CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with non\u2010Hodgkin's lymphoma (NHL) [poster abstract 1136]","volume":"112","author":"DiPersio JF","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood.V112.11.3312.3312","article-title":"12 months report from phase 3 study of plerixafor + G\u2010CSF vs. G\u2010CSF + placebo for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma [poster abstract 3312]","volume":"112","author":"DiPersio JF","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_34_2","volume-title":"Abstracts from the 49th annual meeting of the American Society of Hematology, Atlanta, GA, December 8\u201311, 2007","author":"Micallef I.","year":"2007"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705908"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704486"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705147"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1998.7.241"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130179"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23281"},{"key":"e_1_2_1_41_2","volume-title":"Red book: pharmacy's fundamental reference","author":"Staff PDR","year":"2009"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.5.485","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.5.485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:13:18Z","timestamp":1761045198000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.5.485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1592\/phco.30.5.485"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.5.485","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}